{"id":780929,"date":"2023-08-30T09:04:12","date_gmt":"2023-08-30T13:04:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/"},"modified":"2023-08-30T09:04:12","modified_gmt":"2023-08-30T13:04:12","slug":"equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/","title":{"rendered":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference"},"content":{"rendered":"

<\/p>\n

Equillium to Attend Wells Fargo Healthcare Conference <\/b>& Present at H.C. Wainwright 25th<\/sup> Annual Global Investor Conference<\/b><\/p>\n

LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–Equillium, Inc.<\/a> (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th<\/sup> Annual Global Investor Conference.<\/p>\n

\nManagement will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences.<\/p>\n\n\n\n\n\n\n\n\n
\n

Conference:<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nWells Fargo Healthcare Conference<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nEncore Boston Harbor<\/p>\n<\/td>\n<\/tr>\n

\n

Dates:<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nWednesday, September 6 \u2013 Friday, September 8<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Conference:<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nH.C. Wainwright, 25th<\/sup> Annual Global Investor Conference<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nLotte New York Palace Hotel<\/p>\n<\/td>\n<\/tr>\n

\n

Presentation:<\/b><\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nTuesday, September 12, 7:30 am Pacific Time | 10:30 am Eastern Time<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nWebcast access for the H.C. Wainwright conference will be available on the Events & Presentations<\/a> page under the Investor Relations tab on the Company\u2019s website. An archived replay of the presentation at the H.C. Wainwright conference will be available for 90 days.<\/p>\n

About Equillium<\/b><\/p>\n

Equillium<\/a> is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company\u2019s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in a Phase 1 first-in-human clinical study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase 1b clinical study of patients with lupus\/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd. for the development and commercialization of itolizumab under an option and asset purchase agreement.<\/p>\n

\nFor more information, visit www.equilliumbio.com<\/a>.<\/p>\n

Forward Looking Statements<\/b><\/p>\n

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, \u201ccould\u201d, \u201ccontinue\u201d, “expect”, “estimate”, \u201cmay\u201d, “plan”, “outlook”, \u201cfuture\u201d and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium\u2019s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to statements regarding the intrinsic value and potential of Equillium to generate long-term stockholder value; Equillium\u2019s cash runway; and the ability of Equillium\u2019s capital to fund clinical development efforts through the end of 2024, including through topline data from Equillium\u2019s study of EQ101 in alopecia areata and other milestones, after giving effect to the share repurchase program. Risks that contribute to the uncertain nature of the forward-looking statements include: risks and uncertainties regarding whether, when and on what terms Equillium repurchases its shares of common stock under the program; changes in market conditions and alternative uses of Equillium\u2019s capital, including having to use cash in ways or on timing other than expected; the sufficiency of Equillium\u2019s capital to fund certain clinical development efforts and whether anticipated milestones are able to be achieved; whether Equillium is able to grow its business and increase stockholder value over time; and risks related to Ono\u2019s decision to exercise its option, if ever, to purchase itolizumab or terminate the asset purchase agreement.<\/i>These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission\u2019s website at <\/i>www.sec.gov<\/a><\/i> and on Equillium\u2019s website under the heading \u201cInvestors.\u201d Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230830525918\/en\/<\/a><\/span><\/p>\n

Investor & Media Contact
\n<\/b>
Equillium, Inc.
\n
Michael Moore
\n
Vice President, Investor Relations Officer & Head of Corporate Communications
\n
619-302-4431
\n
ir@equilliumbio.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts California New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference LA JOLLA, Calif.–(BUSINESS WIRE)–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference. Management will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be … <\/p>\n

Continue reading “Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780929","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEquillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference LA JOLLA, Calif.–(BUSINESS WIRE)–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference. Management will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be … Continue reading "Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T13:04:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference\",\"datePublished\":\"2023-08-30T13:04:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/\"},\"wordCount\":886,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/\",\"name\":\"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-08-30T13:04:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference - Market Newsdesk","og_description":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference LA JOLLA, Calif.–(BUSINESS WIRE)–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference. Management will provide an overview of the Company\u2019s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be … Continue reading \"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T13:04:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference","datePublished":"2023-08-30T13:04:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/"},"wordCount":886,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/","name":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-08-30T13:04:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230830525918r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-attend-wells-fargo-healthcare-conference-present-at-h-c-wainwright-25th-annual-global-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780929"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780929\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}